Beatrix Neururer1*#, Lorenza Scarpa1*#, Gianpaolo Di Santo1, Henrik Einspieler1, Rupert Prommegger2 and Irene J Virgolini1
1Department of Nuclear Medicine, Medical University Innsbruck, Austria
2Department of Visceral and General Surgery, Sanatorium Kettenbrücke Innsbruck, Austria
#These authors contributed equally to this work
Papillary Thyroid Cancer (PTC) is a differentiated thyroid cancer and also the most common subtype. The incidence, according to expanding use of imaging techniques, biopsy procedures (mostly fineneedle aspiration) and medical surveillance, along with improved access to healthcare, in the last decades are increased; nevertheless the prognosis is very good, with a life expectancy of 85% after 20 years from thyroidectomy. Almost 15% are more aggressive and can metastasize. Up to 50% PTC spread to cervical lymph nodes but distant metastases (primarily lungs or bone) are very rare. Following surgery, including lymphadenectomy, in case of multifocal localized microcarcinoma (stage pT1a (m)) or up to extensive stage (≥ pT1b) after a positive radioactive iodine uptake scans, therapy with 131I-Nal Radioiodine (RAI) is the most common and effective therapy option. However, PTC may lose the ability to absorb radioiodine and alternative treatment options (such as (re-) surgery, Tyrosinkinase Inhibitors (TKI)) are suitable according to a multidisciplinary decision.
Neururer B, Scarpa L, Di Santo G, Einspieler H, Prommegger R, Virgolini IJ. An Extraordinary Case of Recurring LN-Metastatic Papillary Thyroid Cancer. Clin Surg. 2022; 7: 3476..